Search
rilpivirine (Edurant, RPV)
FDA-approved May 2011
Indications:
- treatment-naive HIV1
- for use in combination with other antiretroviral drugs
Contraindications:
- use during pregnancy (data insufficiency) [2]
- concurrent use of proton pump inhibitor [3]
Dosage:
- PO QD with food*
* requires food & gastric acid for absorption [3]
Adverse effects:
- depression
- insomnia
- headache
- rash
- allegedly fewer adverse effects than efavirenz
Drug interactions:
- proton pump inhibitors interfere with absorption [3]
Laboratory:
- rilpivirine in serum/plasma
Mechanism of action:
- inhibits viral reverse transcriptase
- blocks HIV1 viral replication
Interactions
drug adverse effects of antiretroviral agents
General
non-nucleoside reverse transcriptase inhibitor (NNRTI)
References
- FDA NEWS RELEASE: May 20, 2011
FDA approves new HIV treatment
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256087.htm
- Zuger A
Use of Antiretroviral Drugs in Pregnancy.
Physician's First Watch, April 22, 2014
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- Panel on Treatment of HIV-Infected Pregnant Women and
Prevention of Perinatal Transmission.
Recommendations for use of antiretroviral drugs in pregnant
HIV-1-infected women for maternal health and interventions
to reduce perinatal HIV transmission in the United States.
2014.
AIDSinfo. Clinical Guidelines Portal. March 28, 2014.
http://aidsinfo.nih.gov/Guidelines/HTML/3/perinatal-guidelines/0
(corresponding NGC guideline withdrawn March 2016)
- Medical Knowledge Self Assessment Program (MKSAP) 17,
American College of Physicians, Philadelphia 2015
Component-of
cabotegravir/rilpivirine (Cabenuva)
dolutegravir/rilpivirine (Juluca)
emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF, TAF/FTC/RPV, Complera, Odefsey)